Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Lowering of low-density lipoprotein cholesterol with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of coronary artery disease. However, despite increasing use of statins, a significant number of coronary events still occur and many of such events take place in patients presenting with type 2 diabetes and metabolic syndrome. More and more attention is being paid now to combined atherogenic dyslipidemia which typically presents in patients with type 2 diabetes and metabolic syndrome. This mixed dyslipidemia (or "lipid quartet"): hypertriglyceridemia, low high-density lipoprotein cholesterol levels, a preponderance of small, dense low-density lipoprotein particles and an accumulation of cholesterol-rich remnant particles (e.g. high levels of apolipoprotein B) – emerged as the greatest "competitor" of low-density lipoprotein-cholesterol among lipid risk factors for cardiovascular disease. Most recent extensions of the fibrates trials (BIP – Bezafibrate Infarction Prevention study, HHS – Helsinki Heart Study, VAHIT – Veterans Affairs High-density lipoprotein cholesterol Intervention Trial and FIELD – Fenofibrate Intervention and Event Lowering in Diabetes) give further support to the hypothesis that patients with insulin-resistant syndromes such as diabetes and/or metabolic syndrome might be the ones to derive the most benefit from therapy with fibrates. However, different fibrates may have a somewhat different spectrum of effects. Other lipid-modifying strategies included using of niacin, ezetimibe, bile acid sequestrants and cholesteryl ester transfer protein inhibition. In addition, bezafibrate as pan-peroxisome proliferator activated receptor activator has clearly demonstrated beneficial pleiotropic effects related to glucose metabolism and insulin sensitivity. Because fibrates, niacin, ezetimibe and statins each regulate serum lipids by different mechanisms, combination therapy – selected on the basis of their safety and effectiveness – may offer particularly desirable benefits in patients with combined hyperlipidemia as compared with statins monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 1×
“Bezafibrate, in comparison with other fibrates, has an unique characteristic profile of action since it activates all three PPAR subtypes (alpha, gamma and delta) at comparable doses [25-27].”
de Lemos, J. A., Blazing, M. A., Wiviott, S. D., Lewis, E. F., Fox, K. A. A., White, H. D., Rouleau, J.-L., Pedersen, T. R., Gardner, L. H., Mukherjee, R., et al. (2004) · JAMA · doi:10.1001/jama.292.11.1307 · Cited by 1,333
Manninen, V, Tenkanen, L., Koskinen, P., Huttunen, J. K., Mänttäri, M., Heinonen, O. P., & Frick, M. H. (1992) · Circulation · doi:10.1161/01.cir.85.1.37 · Cited by 1,329
Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans
Sudhop, T., Lütjohann, D., Kodal, A., Igel, M., Tribble, D. L., Shah, S., Perevozskaya, I., & von Bergmann, K. (2002) · Circulation · doi:10.1161/01.cir.0000034044.95911.dc · Cited by 682
Rubins, H. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2597 · Cited by 586 · cited 1×
“Similarly, reduction of cardiovascular disease with gemfibrozil was more pronounced in patients displaying above three of the features of metabolic syndrome [21,22].”
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds
Birjmohun, R. S., Hutten, B. A., Kastelein, J. J. P., & Stroes, E. S. G. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.031 · Cited by 429 · cited 2×
“The flushing issue has been ameliorated by the introduction of slow-release niacins – flushing for these products is approximately 26% [46] – and pre-medication with aspirin.”
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
Tenenbaum, A., Motro, M., & Fisman, E. Z. (2005) · Cardiovascular Diabetology · doi:10.1186/1475-2840-4-14 · Cited by 246 · cited 1×
“Bezafibrate: emerged benefits in metabolic syndrome Bezafibrate, in comparison with other fibrates, has an unique characteristic profile of action since it activates all three PPAR subtypes (alpha, gamma and delta) at comparable doses [ 25-27 ].”
Self-citationBezafibrate in men with lower extremity arterial disease: randomised controlled trial
Meade, T., Zuhrie, R., Cook, C., & Cooper, J. (2002) · BMJ · doi:10.1136/bmj.325.7373.1139 · Cited by 208
The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy
Fazio, S., & Linton, M. F. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0104-8 · Cited by 118
Cited by
Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease
Castañer, O., Pintó, X., Subirana, I., Amor, A. J., Ros, E., Hernáez, Á., Martínez-González, M. Á., Corella, D., Salas-Salvadó, J., Estruch, R., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.10.008 · Cited by 540
Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome
Wang, H. H., Lee, D. K., Liu, M., Portincasa, P., & Wang, D. Q.-H. (2020) · Pediatric Gastroenterology, Hepatology & Nutrition · doi:10.5223/pghn.2020.23.3.189 · Cited by 281
PPAR Agonists and Metabolic Syndrome: An Established Role?
Botta, M., Audano, M., Sahebkar, A., Sirtori, C., Mitro, N., & Ruscica, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041197 · Cited by 253
DUVAL, C., MULLER, M., & KERSTEN, S. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.05.003 · Cited by 199
INDICO, Bandesh, K., Prasad, G., Giri, A. K., Kauser, Y., Upadhyay, M., Basu, A., Tandon, N., & Bharadwaj, D. (2019) · Journal of Human Genetics · doi:10.1038/s10038-019-0591-7 · Cited by 38
Metadata
- Authors
- Tenenbaum, A., Fisman, E. Z., Motro, M., & Adler, Y.
- Venue
- Cardiovascular Diabetology
- Published
- 2006-09-26
- Volume
- 5
- Issue
- 1
- Pages
- 20-20
- ISSN
- 1475-2840 (ISSN-L)
- OpenAlex
- W2149350026
- Cited by
- 86
- References
- 18
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.